Heparin sodium 10 IU/ml IV flush solution

Summary of Product Characteristics Updated 25-Jan-2021 | Fannin UK / Kent Pharma UK Limited

1. Name of the medicinal product

Heparin sodium 10 IU/ml I.V. flush solution

2. Qualitative and quantitative composition

Heparin Sodium Ph. Eur. 10 IU/ml

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Solution for injection.

4. Clinical particulars
4.1 Therapeutic indications

To maintain the patency of in-dwelling intravenous lines.

Not recommended for therapeutic use.

4.2 Posology and method of administration

Method of administration

For injection into the catheter/cannula.

For routine use, 1-5 ml (10-50 IU heparin) should be administered into the catheter/cannula every 4 to 8 hours or as required.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the other excipients listed insection 6.1.

Current or history of heparin-induced thrombocytopenia.

Concomitant use of intravenous diclofenac.

4.4 Special warnings and precautions for use

Heparin Sodium 10 IU/ml i.v. flush solution should be used with caution in patients with hypersensitivity to low molecular weight heparin.

Rigorous aseptic technique should be observed at all times in its use.

As there is a risk of antibody-mediated heparin-induced thrombocytopenia, platelet counts should be measured in patients receiving regular and repeated use of heparin flush solutions for longer than 5 days and the treatment should be stopped immediately in those who develop thrombocytopenia or paradoxical thrombosis andheparin should immediately be eliminated from all flushes and ports.

Repeated flushing of a catheter device with heparin may result in a systemic anticoagulant effect.

4.5 Interaction with other medicinal products and other forms of interaction

When an indwelling device is used for repeated withdrawal of blood samples for laboratory analyses and the presence of heparin or saline is likely to interfere with or alter the results of the tests, the in situ heparin flush solution should be cleared from the device by aspirating and discarding a volume of solution equivalent to that of the indwelling venipuncture device before the desired blood sample is taken.

4.6 Fertility, pregnancy and lactation


The safety of Heparin Sodium 10 I.U/ml Flushing Solution in pregnancy is not established, but the dose of heparin used would not be expected to constitute a hazard.


Heparin is not excreted in breast milk.

4.7 Effects on ability to drive and use machines

Heparin has no or negligible influence on the ability to drive or use machines.

4.8 Undesirable effects

Used as directed, it is extremely unlikely that the low levels of heparin reaching the blood will have any systemic effect, however, there have been rare reports of immune-mediated thrombocytopenia and thrombosis in patients receiving heparin flushes. Pulmonary embolism has been reported as thromboembolic complications of heparin-induced thrombocytopenia.

Hypersensitivity reactions to heparin are rare. They include urticaria, conjunctivitis, rhinitis, asthma, cyanosis, tachypnoea, feeling of oppression, fever, chills, angioneurotic oedema and anaphylactic shock.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

An overdose is unlikely to occur. Bleeding is the main sign of overdose with heparin. As heparin is eliminated quickly, discontinuation of heparinis sufficient in case of minor haemorrhages. In case of severe haemorrhages heparin may be neutralised with protamine sulphate injected slowly intravenously. One mg of protamine sulphate neutralises approximately 100 IU of heparin. Nevertheless, the required protamine sulphate dose varies according to the time of heparin administration and the dose administered.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Heparin is a naturally occurring anticoagulant which prevents the coagulation of blood in-vivo and in-vitro. The dose used to flush indwelling devices is unlikely to produce blood levels of heparin having any systemic effect.

5.2 Pharmacokinetic properties

Not applicable

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium chloride

Water for Injections

6.2 Incompatibilities

This product is compatible with normal saline. Heparin has been reported to be incompatible in aqueous solution with certain substances, e.g. some antibiotics, hydrocortisone, phenothiazines, narcotic analgesics and antihistamines

Heparin and reteplase are incompatible when combined in solution.

Amikacin sulfate, gentamicin sulfate, netilmicin sulfate, pethidine hydrochloride, promethazine hydrochloride and tobramycin sulfate.

If reteplase and heparin are to be given through the same line this, together with any Y-lines, must be thoroughly flushed with a 0.9% saline or a 5% glucose solution prior to and following the reteplase injection.

6.3 Shelf life

2 years.

From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately.

If not used immediately, in-use storage times and conditions are the responsibility of the user.

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

10 x 5 ml ampoules

10 x 10 ml ampoules

Ph Eur Type 1 glass ampoules.

6.6 Special precautions for disposal and other handling

Any portion of the contents not used at once should be discarded.

7. Marketing authorisation holder

Kent Pharma UK Limited

The Bower,

4 Roundwood Avenue,

Stockley Park, Heathrow,

United Kingdom.

UB11 1AF

8. Marketing authorisation number(s)

PL 51463/0033

9. Date of first authorisation/renewal of the authorisation

8 March 1984/21 May 1995.

10. Date of revision of the text


Company Contact Details
Fannin UK / Kent Pharma UK Limited

The Bower, 4 Roundwood Avenue, Stockley Park, Heathrow, UB11 1AF


0845 437 5565

Medical Information Direct Line

+44 (0)1233 506 574

Customer Care direct line

0800 220 280




0845 437 5567

Medical Information e-mail